Search clinical trials for: Crizotinib (Xalkori)

Total 137 results

Pfizer

Completed

A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers

Healthy

United States
Harbin Medical University

Completed

Therapeutic Effect of Crizotinib for Rearrangement-negative, High Phosphorylated ALK Patients

ALK Phosphorylation

China
Pfizer

Completed

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States, United Kingdom
IDEAYA Biosciences

Recruiting

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Metastatic Uveal Melanoma

United States, Canada, Israel, Spain, Australia, Germany, France, Italy, United Kingdom, Netherlands, Belgium, Poland, Switzerland
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

PLATFORM Study of Precision Medicine for Rare Tumors

Rare Tumor
Pfizer

Completed

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

ALK-positive NSCLC

Sweden
University Hospital Regensburg

Completed

Psychometric Properties of the EORTC QLQ-LC29

Lung Cancer

Germany
Pfizer

Completed

Drug Drug Interaction Study Of Crizotinib With Esomeprazole.

Healthy

Belgium
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Shenzhen TargetRx, Inc.
Sun Yat-sen University

Recruiting

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

China
Memorial Sloan Kettering Cancer Center

Completed

Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers

Advanced Lung Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Pfizer

Completed

Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

Solid Tumors

United States, Taiwan, Japan, Korea, Republic of, Russian Federation, Hungary, France, Czechia, Germany, Italy, United Kingdom
National Taiwan University Hospital

Completed

The Effectiveness of Low Carbohydrate Diet in Reducing Polypharmacy for Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus
Pfizer

Completed

Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

Non-Small Cell Lung Cancer

Spain
Jean M. Tersak, M.D.
Pfizer

No longer available

Treatment With Crizotinib Single Patient Expanded Access IND 134375

Inflammatory Myofibroblastic Tumour
Pfizer

Withdrawn

A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer
Shandong University
The Affiliated Hospital of Qingdao University; Qianfoshan Hospital; The Second...

Recruiting

Antineoplastic Drugs in Elderly Patients

Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | BRAF Gene Mutation

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
VA Long Beach Healthcare System

Completed

Comparing TR Band to Statseal in Conjunction With TR Band

Cardiovascular Diseases | Coronary Artery Disease | Atherosclerosis | Angina Pectoris | Arterial Occlusion | Hematoma | Anticoagulant-Induced Bleeding

United States
Pfizer

Completed

A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066

Healthy

Japan
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

ALK-positive NSCLC

China
Pfizer

Completed

Relative Drug Exposures Of Two Formulations of PF-02341066

Healthy

United States
University of Alabama at Birmingham
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas (NF110)

Neurofibromatosis 2 | Progressive Vestibular Schwannoma (VS)

United States
Grupo Español de Investigación en Neurooncología
Pfizer

Completed

Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma

Glioblastoma Multiforme (Grade IV) of Cerebellum

Spain
Hunan Province Tumor Hospital

Recruiting

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation (PIKACHU)

Non Small Cell Lung Cancer | ALK Gene Mutation | MET Gene Mutation | EGFR Gene Mutation | ROS1 Gene Mutation

China
Hunan Province Tumor Hospital

Recruiting

Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Region Stockholm

Recruiting

Normalized Glucose Levels in Type 2 Diabetes With Carbohydrate or Caloric Restriction (CarborCal)

Diabetes Mellitus Type 2 in Obese

Sweden
Pfizer

Completed

Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)

Healthy Participants

United States
Pfizer

Terminated

An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Neoplasms Malignant

United States, Korea, Republic of, Japan, China, Taiwan, Italy, Russian Federation
Pfizer

Completed

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Carcinoma, Non-Small-Cell Lung

United States, Canada, Spain, China, Brazil, United Kingdom, Japan, Poland, Australia, France, Ireland, Taiwan, Italy, Germany, Netherlands, Korea, Republic of, Bulgaria, Greece, Hong Kong, Hungary, Russian Federation, Sweden
Josefin Eklöf

Recruiting

Live Vaccines and Innate Immune Training in COPD. (COPD-LIVE)

COPD | Trained Innate Immunity

Denmark
University of Michigan Rogel Cancer Center
Augusta University

Withdrawn

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

Non-Small Cell Lung Cancer

United States
Pfizer

Completed

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

Non-Small Cell Lung Cancer

United States
Hoffmann-La Roche

Recruiting

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Neoplasms

Italy, France, Turkey, Korea, Republic of, Spain, China, United States, Hong Kong, Russian Federation, Poland
Pfizer
Merck Sharp & Dohme LLC

Terminated

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

ALK-positive Advanced NSCLC

United States
Guangdong Association of Clinical Trials
Chinese Thoracic Oncology Group

Recruiting

Phase II Umbrella Study Directed by Next Generation Sequencing (TRUMP)

Carcinoma, Non-Small-Cell Lung

China
Pfizer

Terminated

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

Non-Small Cell Lung Cancer

United States, Australia, Japan, Korea, Republic of, Spain
Pfizer

Completed

Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy Volunteers

Healthy

United States
Janssen Pharmaceutical K.K.

Completed

An Exploratory Study of Tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back Pain

Osteoarthritis | Low Back Pain
University of Edinburgh
NHS Lothian

Completed

Interaction of Apelin and Angiotensin in the Human Forearm Circulation

Heart Disease | Vasodilation

United Kingdom
Hoffmann-La Roche

Recruiting

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

Carcinoma, Non-Small-Cell Lung

China, France, Croatia, Brazil, Greece, Italy, Mexico, Spain, India, Netherlands, Romania, Sweden, Thailand, Lebanon, Turkey, Germany, Slovakia, Jordan, Russian Federation
National Cancer Institute (NCI)

Terminated

-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer

Adenocarcinoma | Carcinoma, Squamous Cell | Carcinoma, Non-Small Cell Lung | Carcinoma, Large Cell

United States
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

China, Korea, Republic of, Thailand
Hoffmann-La Roche

Active, not recruiting

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (ALEX)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Canada, Taiwan, Australia, France, Hong Kong, Italy, Portugal, Spain, United Kingdom, Brazil, Poland, Guatemala, Singapore, Thailand, Serbia, Ukraine, Bosnia and Herzegovina, China, Costa Rica, E... and more
Pfizer

Completed

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Non Small Cell Lung Cancer

United States, Australia
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.

Urinary Infections

Spain

Search clinical trials for: Crizotinib (Xalkori)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations